|
Exemestane in Reducing Breast Density in Postmenopausal Women at Risk for Breast Cancer Clinical Trials References presented on Clinical Trials Search is not intended to be a substitute for proven healthcare advice, trips or professional assistance by using a real medical. We aren't mDs. Always confer with your physician about Exemestane in Reducing Breast Density in Postmenopausal Women at Risk for Breast Cancer conditions. Clinical Trials Search.org is a website devoted to listing clinical research studies in human subjects. Exemestane in Reducing Breast Density in Postmenopausal Women at Risk for Breast Cancer Clinical research trials and Exemestane in Reducing Breast Density in Postmenopausal Women at Risk for Breast Cancer medical trials take place in hundreds of localities across the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectualness of new does drugs. The purpose of the studies / projects is to solve specific human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to discover treatments for all sorts of conditions, such as Exemestane in Reducing Breast Density in Postmenopausal Women at Risk for Breast Cancer. Exemestane in Reducing Breast Density in Postmenopausal Women at Risk for Breast Cancer Clinical Trials and other clinical trials permit volunteers to access healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for without cost, and every now and again they are compensated for their time. Sometimes there is a cost for a Exemestane in Reducing Breast Density in Postmenopausal Women at Risk for Breast Cancer clinical trial. Subjects often receive the most expert healthcare possible for their Exemestane in Reducing Breast Density in Postmenopausal Women at Risk for Breast Cancer condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, healthcare dangers (perhaps life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with stern guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "E" Clinical Trials Conditions > Exemestane in Reducing Breast Density in Postmenopausal Women at Risk for Breast Cancer  Exemestane in Reducing Breast Density in Postmenopausal Women at Risk for Breast Cancer
Exemestane in Reducing Breast Density in Postmenopausal Women at Risk for Breast Cancer
For Condition: Breast Cancer
Status: Recruiting
Sponsor(s): National Cancer Institute of Canada ,
Synopsis: RATIONALE: High estrogen levels may be associated with dense breast tissue and an increased risk of developing breast cancer. Exemestane may be effective in preventing the development of breast cancer by decreasing estrogen levels and reducing breast density. PURPOSE: Randomized clinical trial to study the effectiveness of exemestane in preventing the development of breast cancer by decreasing estrogen levels and reducing breast density in postmenopausal women who are at increased risk for breast cancer.
Details: OBJECTIVES: - Determine the efficacy of exemestane in decreasing breast density at least 1 grade in postmenopausal women with increased radiological breast density at increased risk for breast cancer. - Determine whether the decrease in breast density is sustained 1 year after the cessation of this drug in these participants. - Correlate the grade of breast density with bone density at baseline and at 1 year in participants treated with this drug. - Determine the overall safety of this drug, in terms of bone and lipid metabolism and toxicity, in these participants. - Determine the menopause-specific quality of life of participants treated with this drug. OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Participants are stratified according to baseline mammographic density grade (2 vs 3 vs 4 vs 5 vs 6). Participants are randomized to 1 of 2 treatment arms. - Arm I: Participants receive oral exemestane once daily for 1 year. - Arm II: Participants receive oral placebo once daily for 1 year. In both arms, treatment continues in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline and then at 3, 6, 9, 12, 18, and 24 months. Participants are followed at 18 and 24 months. PROJECTED ACCRUAL: A total of 120 participants (60 per treatment arm) will be accrued for this study.
Eligibility:
Study Type: Interventional, Prevention
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Radiologically confirmed density occupying at least 25% of the breast tissue on baseline mammogram* - Grade 2, 3, 4, 5, or 6 (Boyd classification) - Participants with different grades between the 2 breasts should be classified according to a higher grade NOTE: *Performed within 6 months before study entry - Bone mineral density T-score of either posterior-anterior spine or hip (femoral neck) must be no greater than 2.0 standard deviations below the mean value of peak bone mass in young normal women as determined by DEXA scan within the past 6 months - No concurrent breast cancer - No prior invasive breast cancer or ductal carcinoma in situ - No breast implants - Hormone receptor status: - Not specified PATIENT CHARACTERISTICS: Age - Postmenopausal Sex - Female Menopausal status - Postmenopausal, defined as 1 of the following: - Over 50 years of age with no spontaneous menses for at least 1 year - 50 years of age and under with no menses (e.g., spontaneous or secondary to hysterectomy) within the past year AND a follicle-stimulating hormone level within institution postmenopausal range - Bilateral oophorectomy Performance status - Not specified Life expectancy - Not specified Hematopoietic - Not specified Hepatic - Not specified Renal - Not specified Cardiovascular - No cardiovascular disease - No history of myocardial infarction - No history of stroke - No uncontrolled high blood pressure Other - No uncontrolled metabolic or endocrine disease - No malabsorption syndrome - No known hypersensitivity to exemestane or its excipients - No other malignancy within the past 5 years except curatively treated squamous cell or basal cell skin cancer or carcinoma in situ of the cervix PRIOR CONCURRENT THERAPY: Biologic therapy - No prior immunotherapy - No concurrent immunotherapy Chemotherapy - No prior chemotherapy - No concurrent chemotherapy Endocrine therapy - More than 3 months since prior exogenous estrogen and/or progesterone/progestin therapy - More than 6 months since prior selective estrogen-receptor modulators (e.g., tamoxifen, toremifene, or raloxifene) - No concurrent selective estrogen-receptor modulators (e.g., tamoxifen, toremifene, or raloxifene) - No concurrent steroids - Vaginal estrogens allowed (e.g., Estring® or Vagifem®) - No concurrent compounded creams Radiotherapy - Not specified Surgery - Not specified Other - More than 4 weeks since prior investigational agents - No other concurrent medications that would preclude study endpoints - No concurrent over-the-counter products or supplements considered to have an estrogenic effect, including any of the following: - Ginseng - Ginkgo biloba - Black cohosh - Dong quai - Fortified soy supplements (e.g., phytoestrogen preparations)
Total Enrollment:
Location and Contact Information:
Overall Study Official:
PaulGoss, Study Chair, Princess Margaret Hospital
Princess Margaret Hospital *Recruiting*
Toronto, Ontario, M5G 2M9
Canada
Recruiting Paul Goss 416-946-4534
Margaret and Charles Juravinski Cancer Centre *Recruiting*
Hamilton, Ontario, L8V 5C2
Canada
Recruiting Andrea Eisen 416-480-4617
Arthur G. James Cancer Hospital - Ohio State University *Recruiting*
Columbus, Ohio, 43210-1240
United States
Recruiting Rebecca Jackson 614-688-3563
Northwestern Ontario Regional Cancer Care *Recruiting*
Thunder Bay, Ontario, P7B 6V4
Canada
Recruiting Adrien Chan 807-684-7200
Centre Hospitalier de l'Universite de Montreal *Recruiting*
Montreal, Quebec, H2L-4M1
Canada
Recruiting Edgard Nassif 514-890-8000 ext. 28006
Brigham and Women's Hospital *Recruiting*
Boston, Massachusetts, 02115
United States
Recruiting Jo Manson 617-732-4965
Additional Information:
Study ID Numbers: CDR0000316328; PHARMACIA-971-ONC-0028-088,CAN-NCIC-MAP2
Study Start Date:
Record last reviewed: January 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00066586
Other Breast Cancer Studies:
1. Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer
2. Conventional Care With or Without Specialized Cancer Care in Treating Patients Receiving Chemotherapy
3. MRI to Detect Breast Tumors in Women
4. LMB-9 Immunotoxin in Treating Patients With Advanced Colon, Breast, Non-small Cell Lung, Bladder, Pancreatic, or Ovarian Cancer
5. Interleukin-11 Plus Filgrastim Prior to Peripheral Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, Breast Cancer, or Other Solid Tumors
Related Studies:
Other Breast Cancer Clinical Trials
Other Ohio Clinical Trials
Other Columbus Clinical Trials
Exemestane in Reducing Breast Density in Postmenopausal Women at Risk for Breast Cancer
|
|
|
|
|
|
|
|
